ArticleBMC public health2021
The feasibility of new HPV/DNA test as a primary cervical cancer screening method among 35- years- old ever-married women in Kalutara district; a cross-sectional study.
Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Penile HPV prevalence among high-risk men in Sri Lanka: baseline insight for HPV prevention strategies in a lower-middle-income country.Infectious agents and cancer · 2026Article
- Penile HPV prevalence and associated factors among 20-70-year-old men from Gampaha district in Sri Lanka: a community-based study in a lower middle-income country.BMC infectious diseases · 2026Article
- Integrating pocket colposcope and telecolposcopy into VIA-based screening at primary healthcare centers for cervical cancer prevention in LMICs.Frontiers in oncology · 2026Review
- Prevalence of CMV, EBV, HPV, and HSV among South Asian healthy population: A systematic review and meta-analysis.PLOS global public health · 2026Article
- A scoping review of evidence on routine cervical cancer screening in South Asia: investigating factors affecting adoption and implementation.Cancer causes & control : CCC · 2025Article
- Population-level cancer screening and cancer care in Bhutan, 2020-2023: a review.The Lancet regional health. Southeast Asia · 2024Review
- A Descriptive Study of Different Methods of Cervical Cancer Screening among Ever-Married Women in 35-Year and 45-Year Cohorts in Kalutara District, Sri Lanka.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Lab-on-chip assay of tumour markers and human papilloma virus for cervical cancer detection at the point-of-care.Scientific reports · 2022Article
- Cervical cancer in Nepal: Current screening strategies and challenges.Frontiers in public health · 2022Review
- Assessing High-Risk HPV Infection Rates in Females Undergoing Cervical Cancer Screening in Western India Using HPV-DNA Testing.Indian journal of community medicine : official publication of Indian Association of Preventive & Social MedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the second commonest female cancer in Sri Lanka. Two major drawbacks of the present cervical cancer screening programme are the suboptimal sensitivity of the pap smear and the low coverage. The objective of the study is to determine the feasibility of a new HPV/DNA test among 35 -years -old ever-married women in a district of Sri Lanka.
methodA community based descriptive cross-sectional study was conducted from 1
resultsOverall response rate was 91.1% (n = 836). Clients' perception was highly positive for HPV/DNA screening test procedure (99.9%, n = 821) and 99.6% (n = 819) of clients had mentioned that the HPV/DNA screening test is worthwhile to be incorporated into the National Cervical Cancer Screening program. The prevalence of HPV was 6.2% (95%CI: 6.18-6.22%). The coverage of the HPV/DNA screening was 89.5%(n = 822). Invalid results reported were 0.12% (n = 1). The percentage of HPV/DNA test positive women who underwent pap test within 3 months of the initial screening was 100% (n = 51), while the percentage of women who attempted to get a colposcopy within the 1 month of referral was 86.7% (n = 13).
conclusionsHPV/DNA test implementation as a primary cervical cancer screening method is feasible among the 35- year age cohort of ever- married women in Kalutara district. It is necessary to further attempt alternative methods of cobas 4800 HPV/DNA test, which would be much suitable for resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.